Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

GlobeNewswire Inc. | Oct 1, 2026 9:01 AM EDT

Application represents an important step in supporting reimbursement